Blueprint Protocol

The Blueprint Protocol is bryan johnson’s closed-loop health system: measure body state, consult scientific evidence, implement interventions, measure again, and update. Johnson treats the body as a system whose organs and biomarkers should have more authority than cravings or cultural defaults.

Design pattern

The protocol has the structure of an autonomous control system:

1. Sensors: bloodwork, imaging, sleep data, fitness tests, oral/skin/organ metrics, epigenetic clocks, and other biomarkers.
2. Objective: reduce speed of aging and optimize organ/biomarker states.
3. Policy: diet, exercise, sleep, supplements, medications, light, heat, oral care, and other interventions.
4. Feedback: repeat measurements and adjust.
5. Public ledger: publish routines/results through the web, X/Twitter, and Blueprint content.

Current protocol stack

The public 2026 protocol emphasizes foundational habits: lower resting heart rate before bed, earlier meals, screens off before bed, consistent sleep, exercise, nutrient-dense food, oral hygiene, skin/hair routines, clean water, and measurement.

Johnson’s May 24, 2026 sleep post adds a tactical version of the same sleep discipline: when expecting to stay up past his 8pm bedtime, he said he took a nap first and argued that “front-loading” sleep is preferable to trying to repay sleep debt afterward because circadian timing still matters. This should be read as Johnson’s personal protocol advice rather than a general medical recommendation.

Johnson’s April 2026 morning routine is an example implementation: 8:30pm bedtime, ~5am wake, oral hygiene, 10,000 lux light, breath work, pre-workout nutrition/supplements, 90 minutes exercise, sauna, red/NIR light, optional shockwave therapy, shower/hair/skincare, and a breakfast of vegetables/legumes/EVOO/berries/nuts/seeds.

On June 19, 2026, a high-engagement routine post compressed that posture into a seven-day checklist: stop food four hours before sleep, screens off 60 minutes before bed, read for 10 minutes before sleep, get light in the eyes on waking, and exercise daily. It is useful as a current, low-tech summary of Johnson’s recurring sleep/wake advice; it should still be presented as his habit framing rather than personalized medical guidance.

Iteration and reversals

The protocol is not static. Johnson’s public posts include stopping or pausing interventions when measurements disappoint. A 2025 @bryan_johnson post says he paused metformin after five years because it appeared to build energy capacity while limiting his ability to use much of it.

Prescription-therapeutics expansion

On June 9, 2026, Johnson announced a prescription medication platform under the Blueprint/Don’t Die umbrella, naming Tadalafil/Cialis, Metformin, Oral Minoxidil, Tretinoin, Estradiol, and Acarbose as prescriptions he personally uses and says are dispensed through licensed doctors and pharmacies. This is a meaningful product expansion from routines, supplements, foods, tests, and certified products into clinician-mediated prescription access.

On June 12, he gave one concrete example: daily 5 mg Tadalafil/Cialis, which he framed as blood-flow/longevity support and not just sexual-health treatment. The public claim cites observational associations with lower mortality and cardiovascular/neurological outcomes, but Johnson’s own post caveats that association is not causation and that the information is not medical advice. The dashboard should preserve that distinction: useful evidence of where Blueprint is moving, not a treatment recommendation.

On June 22, Johnson announced a major expansion of the same prescription layer, now branded Immortals Rx, under the headline “microdose GLP-1s,” “peptides,” and “NAD+.” Newly listed items included semaglutide/Wegovy, tirzepatide/Zepbound, SGLT2 inhibitors Jardiance and Brenzavvy, additional sex/arousal/skin/hair peptide complexes, glutathione, and NAD+, alongside the existing tadalafil/metformin/minoxidil/tretinoin/acarbose stack. This is the strongest public signal so far that the Rx business is widening from a short list of Johnson’s own drugs into GLP-1, peptide, and NAD+ catalogs. It should be presented as Immortals/Blueprint commercial positioning; off-label longevity efficacy and safety are not established by the announcement.

Jet lag and routine snapshots

The June 2026 batch also included self-reported jet-lag recovery timelines and a caffeine + melatonin recovery protocol Johnson said he was testing, plus a breakfast snapshot centered on vegetables, legumes, mushrooms, herbs, seeds, and olive oil. These are examples of the measurement loop in public: an intervention or routine is narrated, tied to biomarkers or recovery, then folded back into the protocol story.

On June 18, Johnson posted the outcome half of that jet-lag test after returning from Australia: 300 mg caffeine in the morning plus 3 mg melatonin before bed, which he said accelerated body-clock resynchronization and was observable “live” via blood glucose. This is useful as protocol logging and follow-up, but still N=1 self-report rather than dosing guidance or proof that the intervention caused recovery.

Microbiome product — Akkermansia + butyrate

The same June 18 source also added a commercial protocol/product signal: Blueprint launched a microbiome supplement pairing Akkermansia muciniphila with butyrate triglycerides. Johnson framed Akkermansia around age-related decline, gut-barrier integrity, glucose regulation, insulin sensitivity, and Amuc_1100/TLR2 signaling, while framing butyrate triglycerides as direct epithelial support. The dashboard should separate those mechanism claims from product-specific evidence; the launch is notable, but not independent validation of gut or metabolic benefit.

Skin / UV protection

On June 19, 2026, Johnson posted a skin-aging self-measurement from his Australia trip: he claimed one week of Australian sun increased his skin aging by about 5% via UV damage/spots despite umbrella and peak-UV protection, then added in a reply that he has reversed his skin age by roughly 9 years since starting the project. He cited a 1,472-person comparison where Australian women showed skin-aging signs 10–20 years earlier than US women, but did not provide a full citation in-tweet. For the dashboard, this is best treated as another Blueprint readout example — skin/UV risk quantified as a metric — not independent validation of the 5% or 9-year figures and not individualized skincare advice.

Sauna heat-dose / HSP27 testing

On June 16, 2026, Johnson posted a three-session dry-sauna experiment using an ingestible temperature capsule with 30-second core-temperature readings, repeated blood draws, and specialty biomarkers. His stated question was whether sauna benefit depends on elapsed time or on body-temperature dose. Johnson claims HSP27 increased only in sessions where his core temperature stayed above 102.2°F / 39°C for roughly 15 minutes, while a shorter time above that threshold did not produce the same response.

This is useful for the dashboard because it shows Blueprint’s protocol-iteration style: define a measurable mechanism, track delivered dose inside the body, compare response, then revise the practical rule. It should not be rendered as a public sauna prescription. Extreme heat exposure can be risky, and Johnson’s thread remains N=1 biomarker evidence rather than independent proof of clinical longevity benefit.

A June 17 follow-up added a heart-rate trace from the same 56-minute 200°F / 93°C session, with Johnson reporting a 128–133 bpm peak and a spike when changing ice on his face, neck, and groin. The extra datapoint is dashboard-useful mainly because it shows how Blueprint experiments now publish physiological traces alongside biomarker claims; it does not change the N=1 status or safety caveats.

N-of-1 methodology essay (June 2026)

The same daily batch included Johnson’s most formal public defense of Blueprint’s method to date, prompted by a Nature feature. With the Blueprint & Immortals Medical and Science Team, he argued that RCTs remain the gold standard for population average effects and safety, but are structurally limited for tuning individualized intervention combinations over time. For the public KB, this is best treated as a methodology update: it clarifies why Blueprint keeps emphasizing dense personal measurement, while also making the evidence boundary explicit because the essay’s examples are still observations needing validation.

Critical context: changes are hard to interpret because dozens of variables move at once. In conventional evidence hierarchy, this is hypothesis-generating self-experimentation, not proof of general efficacy.

Automation analogy

Johnson explicitly connects Blueprint to automation: in a 2024 X post he wrote that the era is defined by automation in software engineering, self-driving, and health/wellness, and that Blueprint is automation toward peak health and age escape velocity.

This makes Blueprint relevant to the wiki’s AI-agent themes: it is essentially an agentic/self-driving loop over the body, with measurements as context, protocols as tools, and biological age as reward signal.

Evidence tiers

Related pages

• blueprint
• bryan johnson
• dont die
• algorithmic health — the broader measurement-and-policy pattern behind the protocol.